It has also been reported that the GPX4 inhibitors RSL3 and ML210 can disrupt the antioxidant system [89] and ferroptosis in many drug-tolerant cancer cells (e.g., melanoma, breast, lung, and ovarian cancer cells) in vitro and prevent tumor relapse [123]. The gene discussed is GPX4; the disease is cancer.